Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06318793 Completed - Clinical trials for Peritoneal Carcinomatosis

Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis

Start date: September 2012
Phase:
Study type: Observational

A retrospective study of a single-center prospective database of patients who underwent curative CRS-HIPEC for peritoneal carcinomatosis (PC) of colo-rectal cancer (CRC), between September 2012 and July 2023 at Reims Hospital-University was conducted. Inclusion criteria were: patients older than 18 years with a performance status ≤ 2, who underwent complete (no macroscopic residual disease) CRS-HIPEC was performed. Exclusion criteria were the presence of an infectious disease prior to surgery, CRS without HIPEC, incomplete CRS and expressed refusal to participate in the study. During the month prior to surgery, patients underwent a thorough diagnostic workup, including chest and abdominopelvic computed tomography (CT) scans, complete haematological and biochemical tests, and cytobacteriological analysis of urine. Blood tests included leukocytes, neutrophils, lymphocytes, platelet count, albumin and CRP. Within one week before surgery, patients were examined by both the surgeon and the anaesthetist. Variables with a normal distribution are presented as mean-SD, while those with a non-normal distribution are presented as median and range. Categorical variables are presented as counts and percentages. Chi-Square or Fisher's exact test was used to compare qualitative variables. Linear regression analysis was used to assess any association between preoperative inflammatory biomarkers and patient comorbidities and disease characteristics. Preoperative levels of inflammatory biomarkers were compared between patients with no postoperative complication (POC) and patients with POC and major POC using the non-parametric Mann-Whitney U test. Optimal cut-off values for significant inflammatory biomarkers were determined using the Youden index. Receiver operating curves (ROC) were calculated to determine the area under the curve (AUC). Univariable and multivariable analyses including cut-off values of significant biomarkers were performed in a binary logistic regression analysis and expressed as odds ratios (OR). All tests were two-tailed and results were considered significant if the p-value was < 0.05. Statistical analyses were performed using R software (version 4.0.5).

NCT ID: NCT06315101 Completed - Clinical trials for Unresectable Hepatocellular Carcinoma

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

Start date: September 1, 2023
Phase:
Study type: Observational

This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China.

NCT ID: NCT06314711 Completed - Clinical trials for Oropharyngeal Squamous Cell Carcinoma

Ex Vivo 3D-ultrasound for Oropharyngeal Cancer

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Patients with biopsy-verified oropharyngeal squamous cell carcinoma or Human Papillomavirus (HPV)-positive unknown primary treated with transoral robotic surgery are included. Immediately post-operatively, freshly resected specimens are examined with ex vivo 3D ultrasound (US). Ex vivo 3D US will be used to match US slices of the specimen with corresponding histopathology slices. The US slices will be reviewed by a panel of head and neck surgeons blinded to histopathology. The primary aim is to explore perioperative ex vivo 3D US for oropharyngeal tumor detection, delineation from normal tissue, tumor size and volume, and margin assessment.

NCT ID: NCT06313047 Completed - Clinical trials for Hepatocellular Carcinoma

Pharmacogenetic of Doxorubicin in HCC.

Start date: January 1, 2021
Phase:
Study type: Observational

The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.

NCT ID: NCT06309459 Completed - Clinical trials for Triple Negative Breast Cancer

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

Start date: August 1, 2018
Phase:
Study type: Observational

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

NCT ID: NCT06305130 Completed - Clinical trials for Carcinoma, Transitional Cell (RENI)

Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma

Start date: January 1, 1988
Phase:
Study type: Observational

Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Methods: multicentered cohort study

NCT ID: NCT06298123 Completed - Clinical trials for Hepatocellular Carcinoma

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Start date: February 1, 2019
Phase:
Study type: Observational

The aim of this study was to analyse the independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after liver resection surgery, and to develop a prognostic model based on these factors.

NCT ID: NCT06265883 Completed - Clinical trials for Hepatocellular Carcinoma Non-resectable

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Start date: July 1, 2019
Phase:
Study type: Observational

This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021. Tumor response, time to progression (TTP), overall survival (OS), and treatment-related adverse events (TRAEs) were compared between the two groups.

NCT ID: NCT06261138 Completed - Clinical trials for Hepatocellular Carcinoma

Survival Analysis: TACE vs. Combination Therapy in HCC

Start date: February 1, 2019
Phase:
Study type: Observational

This retrospective observational study aimed to assess potential improvements associated with systemic therapies in patients receiving transarterial chemoembolization (TACE) for initially unresectable HCC.

NCT ID: NCT06259838 Completed - Clinical trials for Oral Cavity Squamous Cell Carcinoma; Readmission

Oral Cavity Squamous Cell Carcinoma and Readmission: Rates, Causes, and Risk Factors.

Start date: January 1, 2023
Phase:
Study type: Observational

We sought to comprehend the rates and causes of unplanned hospital readmission within 60 days following oral cancer surgery